Objectives: To examine the epidemiology of b-lactam resistance in 'clonal group 258' (CG258), a successful KPC clonal group, over 14 years.
Introduction
Clinical carbapenem resistance in Enterobacteriaceae was first reported in the USA in 1986, one year after the introduction of imipenem/cilastatin, with 1.3% of Enterobacter isolates exhibiting resistance in the period from 1986 to 1988. 1 Historically, the first description of KPC came from a North Carolina isolate collected in 1996. 2 Carbapenem resistance among Enterobacteriaceae in the USA is most commonly encoded by bla KPC . The bla KPC gene is carried on Tn4401, which, via transposition events, incorporates into compatible plasmids. These plasmids in turn may be transmitted within a single Enterobacteriaceae species or between Enterobacteriaceae species. 3 ST258 is the most frequent ST associated with carbapenem resistance and it comprises 56% of KPC-producing Klebsiella pneumoniae isolates in a global sample and 63% in a study from a large US academic centre. 4 ,5 ST258, first described in 2009, is a hybrid clone that evolved from the recombination between older ST11 and ST442. 6, 7 ST258 isolates were identified retrospectively as early as 2003 in New York and rapidly spread to other parts of the USA. 8, 9 Among ST258 bla KPC -containing isolates, there are two predominant capsular polysaccharide types, cps-1 (wzi29) and cps-2 (wzi154). 10 bla KPC is most commonly associated with plasmids of IncFIA and IncFII and, less frequently, IncI2, IncL/M, IncN and IncX. 11 Over 30 bla KPC types have been identified to date (https:// www.ncbi.nlm.nih.gov/nuccore?term"313047); however, types 2 and 3 predominate in the USA, each comprising 50% of isolates in one retrospective analysis of archived isolates. 12 New York City remains an epicentre of the carbapenem-resistant Enterobacteriaceae (CRE) epidemic. In this study, we performed a retrospective molecular analysis of strain types, capsular polysaccharide types and plasmid types present in both carbapenem-resistant K. pneumoniae and carbapenem-susceptible K. pneumoniae isolates collected between 1999 and 2013 in New York City. The aim of this retrospective analysis was to answer whether 'clonal group 258' (CG258) was the predominant K. pneumoniae strain type among carbapenem-resistant K. pneumoniae at the onset of the carbapenem resistance epidemic and whether early CG258 bla KPC strains were either cps-1 or cps-2 and had similar plasmids to those circulating in 2013.
Materials and methods
Isolates were collected as part of periodic epidemiological surveillance of all Gram-negative organisms regardless of antimicrobial susceptibility or source. All hospitals in the borough of Brooklyn were included. The number of participating hospitals decreased from 14 to 8 between 1999 and 2013 but this decrease was a result of closures of hospitals and hospital microbiology labs. All hospitals covering the borough of Brooklyn were included in each collection. Because clinical information was unavailable for most isolates, we could not identify whether organisms isolated from urine and sputum reflected infection or colonization. Therefore, we focused on bloodstream isolates only. Only K. pneumoniae isolates were included in the study. A total of 515 bloodstream isolates had antibiotic susceptibility data available. Forty-four isolates were physically missing and 35/471 isolates did not grow on culture.
Each collection spanned 3 months during 1999, 2003-04, 2006, 2009 and 2013 . Isolates were identified by automated identification and susceptibility platforms at each hospital. MICs of imipenem, ertapenem and meropenem were obtained by the agar dilution method as well as those of drugs from clinically relevant antibiotic classes. MICs were interpreted using CLSI breakpoints. 13 Determining whether a K. pneumoniae isolate belonged to CG258 was assessed by multiplex RT-PCR testing (Stratagene Mx3005P, Agilent Technologies, Santa Clara, CA, USA) using two molecular beacon probes targeting C118T and A297C substitutions in the tonB79 sequence. Separate primers and probes were used to detect all known bla KPC variants. An internal positive-control probe for a sequence from K. pneumoniae gapA was included to confirm DNA quality. All primer and probe sequences were previously published by Chen et al. 14 MLST, for a subset of isolates, and wzi alleles of all CG258 isolates were defined by sequencing PCR amplicons using the method described previously. 10, 15 Resulting sequences were compared with existing alleles and STs in the Institut Pasteur Klebsiella Sequence Typing database (http:// bigsdb.pasteur.fr/klebsiella/klebsiella.html). MLST performed on non-CG258 isolates showed no STs with a prevalence of more than a few percent.
PCR for common ESBL and AmpC genes was performed using a previously described RT-PCR method, which is capable of detecting the SHV-and TEM-type ESBLs by a linear-after-the-exponential PCR (LATE-PCR) melting curve analysis 16 PCR assays were performed for the common pKpQIL and pBK30683 plasmids previously associated with carbapenem resistance, as previously described.
9 Tn4401 isoform and bla KPC type PCR was performed, as previously described, for all CG258 isolates. 8 Data were analysed using SPSS 17.0.
Results
Antimicrobial susceptibilities were available for 515 isolates and 436 were available for sequence typing. Fifty-six isolates screened positive for CG258 by PCR. Carriage of bla KPC and ESBL by year is shown in Table 1 . Only one isolate tested positive for an AmpC gene (bla CMY-2 ). Thirty-eight of 56 CG258 isolates harboured bla KPC ; 28/38 were KPC-2 and 10/38 were KPC-3. Among 18 bla KPC -negative isolates, all but one was phenotypically susceptible to carbapenems. The resistant isolate was genotypically negative for all carbapenemases tested, but was found to harbour an SHVtype ESBL and mutations in the ompK35 and ompK36 porin genes. The first CG258 isolate to contain bla KPC-2 was identified in 2003, with bla KPC-3 appearing in 2006. SHV-type ESBL was the most common ESBL, present in 50% (19/38) of bla KPC -harbouring CG258 isolates; bla CTX-M-1 and bla CTXM-2 were each identified in a single isolate. No TEM-type ESBL was detected.
Sequencing of wzi showed wzi29 (21/56) and wzi154 (21/56) were the most prevalent alleles with others comprising 14/56. Among KPC-2 isolates, 19/28 were wzi29 (cps-1), 7/28 were wzi154 (cps-2), 1/28 was wzi83 and 1/28 was wzi150. KPC-3 isolates were predominantly wzi154 (cps-2) (8/10) and 2/10 were wzi29. Among KPC-negative isolates, 6/18 were wzi154 (cps-2). Five of six were carbapenem susceptible, of which three carried bla SHV and one carried both bla CTX-M-2 and bla SHV.
Isolate data including ESBL, bla KPC and common plasmid carriage and Tn4401 isoforms are shown in Table 2 . Among bla KPCharbouring isolates, Tn4401a was identified in 28/38, Tn4401b in 2, and Tn4401d in 6, and no amplification observed in 2. PCR assays for the pKpQil FII-type bla KPC -containing plasmid were positive in 16/38 bla KPC -harbouring isolates: 6/7 in 2003, 2/13 in 2006, 7/16 in 2009 and 1/2 in 2013. PCR assays for the pBK30683 FI-type bla KPC -containing plasmid were positive for 6/38 carbapenemnon-susceptible isolates (2 in 2006 and 4 in 2009). Among bla KPCnegative CG258 isolates, three isolates were found to carry the pBK30683 replicon and one the pKpQIL replicon.
Discussion
In this study, the ST258 clonal group, defined as ST258 and its single allele variants, was absent in New York City K. pneumoniae isolates in 1999, but highly prevalent in 2003. During the emergence of the CRE epidemic in New York City, CG258 isolates rapidly acquired SHV-mediated ESBL resistance and bla KPC . Isolates carrying ESBL without bla KPC and isolates carrying neither ESBL nor bla KPC were most common at the onset of the epidemic. The phenotypically susceptible CG258 isolates commonly carried cps-2. The earliest bla KPC-2 -positive isolates, from 2003, predominantly carried cps-2 capsule type, suggesting that this was the initial capsular polysaccharide type in ST258 isolates. Notably, a third of CG258 isolates were susceptible to carbapenems, suggesting that carbapenem resistance arose by a combination of both plasmid Eilertson et al. Tn4401a  SHV  47089  2006  R  KPC-2  Tn4401a  SHV  47095  2006  R  KPC-2  SHV  47098  2006  R  KPC-2  Tn4401a  47099  2006  R  KPC-2  Tn4401a  47063  2006  R  KPC-3  Tn4401d  pBK30683-like  SHV  47066  2006  R  KPC-3  Tn4401d  pBK30683-like  SHV  47081  2006  R  KPC-3  Tn4401b  47176  2009  S  -47345  2009  S  -47163  2009  R  KPC-2  Tn4401a  pKpQIL-like  47164  2009  R  KPC-2  Tn4401a  pKpQIL-like  47165  2009  R  KPC-2  Tn4401a  SHV  47168  2009  R  KPC-2  Tn4401a  SHV  47170  2009  R  KPC-2  Tn4401a  SHV  47172  2009  R  KPC-2  Tn4401a  47174  2009  R  KPC-2  Tn4401a  pKpQIL-like  47175  2009  R  KPC-2  Tn4401a  SHV  47177  2009  R  KPC-2  Tn4401a  pKpQIL-like  47178  2009  R  KPC-2  Tn4401a  pKpQIL-like  SHV  47153  2009  R  KPC-3  Tn4401d  pBK30683-like  47154  2009  R  KPC-3  Tn4401a  pKpQIL-like  47155  2009  R  KPC-3  Tn4401a  pKpQIL-like  47161  2009  R  KPC-3  Tn4401d  pBK30683-like  SHV  47162  2009  R  KPC-3  Tn4401d  pBK30683-like  SHV  47166  2009  R  KPC-3  Tn4401d  pBK30683- In our samples, SHV-type b-lactamase was the predominant mechanism of ESBL resistance. AmpC and bla CTX-M carriage was rare. As expected, no bla TEM -mediated resistance was detected. The oldest CG258 isolates identified were collected in 2003. In the initial study describing ST258, isolates collected between 1996 and 2008 were assessed, but the year of collection for these isolates is not described. 7 Our CG258 isolates from 2003 and 2006 in some cases carried only bla SHV -mediated resistance, while later bla KPCcarrying isolates in many cases lacked common ESBL genes. Prior studies of bla KPC -producing isolates revealed co-carriage of bla SHV in 50% of isolates collected between 2008 and 2010. 17, 18 The distribution of KPC-2 and KPC-3 isolates observed in our study was similar to the 69.6% KPC-2 and 29.5% KPC-3 observed in a large multinational study. 19 Specific PCR was performed for two plasmids previously implicated in bla KPC carriage in New York City. Specifically, pKpQIL is a common bla KPC -bearing conjugative plasmid from the IncFII group, identified in Israel and subsequently identified in the USA, 20 while pBK30683 is a conjugative IncFIA plasmid associated with KPC-3, found in 16% of KPC-producing K. pneumoniae isolates from New York and New Jersey. 12 Together, plasmids homologous to these two types were identified in 50% of carbapenem-nonsusceptible isolates. Plasmid conjugation efficiency was noted to be highest for pKpQIL among eight clinically derived bla KPC plasmids evaluated, which may contribute to the high observed frequency of pKpQIL-like plasmids observed in our sample. 21 All 16 isolates with pKpQIL-like plasmids carried the Tn4401a isoform and 15/16 were KPC-2. All six isolates carrying the pBK30683-like plasmid carried the Tn4401d isoform with KPC-3. The decrease in bla SHV carriage in the presence of pKpQIL-like plasmids suggests it is carried on a different plasmid or that multiple pKpQIL-like plasmids are circulating.
Among early KPC-negative isolates, wzi154 (cps-2) was the most prevalent capsular type, suggesting this was the initial capsular type in ST258. In KPC-2, wzi29 (cps-1) has largely supplanted wzi154 (cps-2) as the dominant capsular type, while, in KPC-3, wzi154 (cps-2) has remained the dominant capsular type. In a study of carbapenem-resistant K. pneumoniae isolates collected in 2013 from New York City, 51% of KPC-2 isolates were wzi29 (cps-1) and 93% of KPC-3 isolates were wzi154 (cps-2). Patients infected with wzi154 (cps-2) capsular type isolates had increased levels of 30 day mortality; however, the reason is unknown. 22 This study is inherently limited as a result of being a retrospective and observational investigation. The hospitals participating in the study were primarily community hospitals with only one participating hospital performing solid organ transplants and none performing liquid transplants. Also, we included only bloodstream isolates in this study because of the lack of patient data on the samples. Without patient data, we were unable to distinguish whether wound, respiratory and urine samples represented infection or colonization. Because of missing isolates, we cannot estimate prevalence rates for the participating hospitals.
Regardless of its limitations, we did successfully identify the dissemination of CG258 in New York City prior to the acquisition of carbapenem resistance. Since that time, rates of ESBL carriage, capsular types and prevalent KPC subtypes varied considerably underscoring the plasticity of CG258. The presence of carbapenemsusceptible CG258 isolates at the start of the epidemic highlights the need for ongoing surveillance for the next highly successful genetic background for b-lactamase resistance. Eilertson et al.
